# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.
HC Wainwright & Co. analyst Mitchell Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price t...
RBC Capital analyst Luca Issi reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform and maintains $24 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $22 pri...
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.